Wall Street analysts expect Tempest Therapeutics to report a consensus EPS of -$0.32 on zero revenue for Q3 2026, with the current stock price of $0.51 trading well below the average analyst price target of $7.00.

Investors are primarily focused on clinical pipeline updates, specifically the progress of lead candidate TPST-1120 and the timeline for a planned pivotal study in liver cancer.

The company recently underwent leadership changes, including the appointment of a new CFO, and secured approximately $6 million in funding via warrant exercises to extend its cash runway.

Clinical progress for TPST-2003, a dual-targeting CAR-T candidate, also remains a key point of interest following recent positive interim data and manufacturing milestones.